S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.41
Log in

Eidos Therapeutics Stock Forecast, Price & News

+1.63 (+1.29 %)
(As of 01/19/2021 12:00 AM ET)
Today's Range
Now: $128.14
50-Day Range
MA: $118.03
52-Week Range
Now: $128.14
Volume343,607 shs
Average Volume129,137 shs
Market Capitalization$4.98 billion
P/E RatioN/A
Dividend YieldN/A
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Eidos Therapeutics logo


Overall MarketRank

0.99 out of 5 stars

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EIDX



Sales & Book Value

Annual Sales$26.69 million
Book Value$4.57 per share


Net Income$-37,830,000.00


Market Cap$4.98 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableNot Optionable
+1.63 (+1.29 %)
(As of 01/19/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EIDX News and Ratings via Email

Sign-up to receive the latest news and ratings for EIDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Eidos Therapeutics (NASDAQ:EIDX) Frequently Asked Questions

How has Eidos Therapeutics' stock been impacted by Coronavirus?

Eidos Therapeutics' stock was trading at $43.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EIDX stock has increased by 192.0% and is now trading at $128.14.
View which stocks have been most impacted by COVID-19

Is Eidos Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eidos Therapeutics in the last twelve months. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Eidos Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EIDX, but not buy additional shares or sell existing shares.
View analyst ratings for Eidos Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Eidos Therapeutics?

Wall Street analysts have given Eidos Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eidos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eidos Therapeutics' next earnings date?

Eidos Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Eidos Therapeutics

How were Eidos Therapeutics' earnings last quarter?

Eidos Therapeutics, Inc. (NASDAQ:EIDX) released its quarterly earnings results on Thursday, October, 29th. The company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.71) by $0.08. The company earned $0.13 million during the quarter.
View Eidos Therapeutics' earnings history

What price target have analysts set for EIDX?

10 analysts have issued 12-month target prices for Eidos Therapeutics' shares. Their forecasts range from $34.00 to $80.00. On average, they anticipate Eidos Therapeutics' share price to reach $59.04 in the next year. This suggests that the stock has a possible downside of 53.9%.
View analysts' price targets for Eidos Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Eidos Therapeutics?

Eidos Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 501,500 shares, a decrease of 21.3% from the December 15th total of 637,100 shares. Based on an average daily volume of 238,900 shares, the days-to-cover ratio is currently 2.1 days. Currently, 3.8% of the shares of the stock are sold short.
View Eidos Therapeutics' Short Interest

Who are some of Eidos Therapeutics' key competitors?

What other stocks do shareholders of Eidos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eidos Therapeutics investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Micron Technology (MU), Pfizer (PFE), Verastem (VSTM), ImmunoGen (imgn), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY) and Axsome Therapeutics (AXSM).

Who are Eidos Therapeutics' key executives?

Eidos Therapeutics' management team includes the following people:
  • Dr. Neil Kumar, CEO & Director (Age 41, Pay $247.68k)
  • Dr. Uma Sinha, Chief Scientific Officer & Director (Age 63, Pay $533.4k)
  • Dr. Cameron Turtle Ph.D., Chief Bus. Officer (Age 30, Pay $578.4k)
  • Dr. Jonathan C. Fox FACC, M.D., Ph.D., Pres & Chief Medical Officer (Age 63)
  • Dr. Isabella Graef M.D., Co-Founder & Board Advisor (Age 55)
  • Dr. Mamoun Alhamadsheh Ph.D., Pharm.D., Co-Founder
  • Mr. Franco Valle, Sr. VP of Fin., Principal Accounting Officer & Sec. (Age 39)
  • Mr. Matt Outten, Chief Commercial Officer
  • Dr. Hoyoung Huh, Consultant (Age 51)

When did Eidos Therapeutics IPO?

(EIDX) raised $101 million in an IPO on Wednesday, June 20th 2018. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Barclays was co-manager.

What is Eidos Therapeutics' stock symbol?

Eidos Therapeutics trades on the NASDAQ under the ticker symbol "EIDX."

How do I buy shares of Eidos Therapeutics?

Shares of EIDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eidos Therapeutics' stock price today?

One share of EIDX stock can currently be purchased for approximately $128.14.

How big of a company is Eidos Therapeutics?

Eidos Therapeutics has a market capitalization of $4.98 billion and generates $26.69 million in revenue each year. The company earns $-37,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Eidos Therapeutics employs 70 workers across the globe.

What is Eidos Therapeutics' official website?

The official website for Eidos Therapeutics is www.eidostx.com.

How can I contact Eidos Therapeutics?

Eidos Therapeutics' mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-887-1471 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.